Intravenous immunoglobulin for dermatomyositis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Intravenous Immunoglobulin for Dermatomyositis." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/455483/all/Intravenous_immunoglobulin_for_dermatomyositis.
Intravenous immunoglobulin for dermatomyositis. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/455483/all/Intravenous_immunoglobulin_for_dermatomyositis. Accessed October 13, 2024.
Intravenous immunoglobulin for dermatomyositis. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/455483/all/Intravenous_immunoglobulin_for_dermatomyositis
Intravenous Immunoglobulin for Dermatomyositis [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 October 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/455483/all/Intravenous_immunoglobulin_for_dermatomyositis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Intravenous immunoglobulin for dermatomyositis
ID - 455483
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/455483/all/Intravenous_immunoglobulin_for_dermatomyositis
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -